Skip to main content
. 2018 Dec 1;8(12):2359–2376.

Figure 2.

Figure 2

Number of alterations in 14 PI3K-AKT-mTOR signaling genes and 9 cell-cycle pathway genes in patients with ER+ breast cancer at Avera: Alterations in genes in patients with breast cancers enrolled at Avera Cancer Institute with ER+ disease were evaluated for the study. We identified alterations in 14 PI3K-AKT-mTOR pathway genes and 9 cell-cycle pathway genes in 129 patients with ER+ breast cancer at Avera. Alterations of genes were determined from the reports of Foundation Medicine (for DNA sequencing). Genes of the PI3K pathway is altered in 109 patients out of 129 ER+/PR+BC patients (84%; n = 129). A number of alterations of the PI3K pathway showed that the highest alterations were observed in the PIK3CA gene (A). Genes of the cell-cycle pathway are altered in 46 patients out of 129 ER+/PR+BC patients (35.6%; n = 129). A number of alterations of the cell-cycle pathway showed that the highest alterations were observed in the CCND1 gene (B). Percentage of alterations and co-alterations of the PI3K, and cell-cycle pathway genes in ER+BC patients showed 23% of co-alterations (C). Distribution of co-alterations of the PI3K and cell-cycle pathways in ER+BC in Avera showed that co-alterations are predominantly present in patients with metastatic diseases (D).